S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Price, News & Analysis

$0.90
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.88
$0.94
50-Day Range
$0.80
$1.05
52-Week Range
$0.67
$3.37
Volume
1.16 million shs
Average Volume
861,360 shs
Market Capitalization
$65.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Kezar Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
1,120.1% Upside
$11.00 Price Target
Short Interest
Bearish
4.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.96mentions of Kezar Life Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.21 out of 5 stars

Medical Sector

182nd out of 938 stocks

Pharmaceutical Preparations Industry

76th out of 435 stocks

KZR stock logo

About Kezar Life Sciences Stock (NASDAQ:KZR)

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

KZR Stock Price History

KZR Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Kezar Life Sciences, Inc. (KZR)
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
Kezar Life Sciences Inc.
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
Kezar Life Sciences Inc KZR
KZR Jan 2025 17.500 call
Analyst Expectations for Kezar Life Sciences's Future
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$20.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,120.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-101,870,000.00
Pretax Margin
-1,455.29%

Debt

Sales & Book Value

Annual Sales
$7 million
Book Value
$2.58 per share

Miscellaneous

Free Float
67,050,000
Market Cap
$65.64 million
Optionable
Not Optionable
Beta
0.48
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


KZR Stock Analysis - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares.
View KZR analyst ratings
or view top-rated stocks.

What is Kezar Life Sciences' stock price target for 2024?

3 brokers have issued twelve-month price targets for Kezar Life Sciences' stock. Their KZR share price targets range from $2.00 to $20.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 1,120.1% from the stock's current price.
View analysts price targets for KZR
or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2024?

Kezar Life Sciences' stock was trading at $0.9474 at the start of the year. Since then, KZR shares have decreased by 4.8% and is now trading at $0.9016.
View the best growth stocks for 2024 here
.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KZR earnings forecast
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Avidity Partners Management LP (6.91%), Vanguard Group Inc. (4.21%), Vanguard Group Inc. (4.21%), Granahan Investment Management LLC (2.62%), Northern Trust Corp (0.75%) and Goldman Sachs Group Inc. (0.61%). Insiders that own company stock include Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KZR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners